Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Clopidogrel for Acute Ischaemia of Recent Onset

First Posted Date
2016-05-18
Last Posted Date
2019-02-12
Lead Sponsor
Ain Shams University
Target Recruit Count
188
Registration Number
NCT02776540
Locations
🇪🇬

Ain Shams University Hospitals, Cairo, Egypt

Cilostazol Following Peripheral Endovascular Procedures

First Posted Date
2016-05-12
Last Posted Date
2021-01-12
Lead Sponsor
Attikon Hospital
Target Recruit Count
200
Registration Number
NCT02770274
Locations
🇬🇷

Patras Universityu Hospital, Patras, Achaia, Greece

🇬🇷

Attikon university General Hospital, Athens, Attiki, Greece

Effect of Aspirin on Gut Microbiome

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-05-04
Last Posted Date
2020-06-26
Lead Sponsor
University of Minnesota
Target Recruit Count
50
Registration Number
NCT02761486
Locations
🇺🇸

Epidemiology Clinical Research Center, Minneapolis, Minnesota, United States

Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer

First Posted Date
2016-05-02
Last Posted Date
2016-05-02
Lead Sponsor
West China Hospital
Target Recruit Count
100
Registration Number
NCT02757365
Locations
🇨🇳

West Hospital of China, Chengdu, Sichuan, China

Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2016-04-22
Last Posted Date
2019-02-15
Lead Sponsor
Fudan University
Target Recruit Count
52
Registration Number
NCT02748304
Locations
🇨🇳

Huashan hospital, Shanghai, China

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

First Posted Date
2016-04-22
Last Posted Date
2019-03-21
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
40
Registration Number
NCT02748330
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Continuing Low Dose Aspirin Before Prostate Biopsy

Phase 4
Conditions
Interventions
First Posted Date
2016-04-20
Last Posted Date
2016-04-20
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
150
Registration Number
NCT02744937

Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2016-04-20
Last Posted Date
2016-04-20
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
114
Registration Number
NCT02744716
Locations
🇨🇳

the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-04-18
Last Posted Date
2021-03-17
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
20
Registration Number
NCT02741817
Locations
🇬🇧

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3
Recruiting
Conditions
Interventions
Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Moxifloxacin or Levofloxacin
Drug: Extended course macrolide
Drug: Fixed-duration Hydrocortisone
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Eritoran
Drug: Cysteamine
Drug: Imatinib
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Angiotensin Receptor Blockers
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Intermediate dose thromboprophylaxis
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Amoxicillin-clavulanate
Drug: Fixed-duration dexamethasone
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil
First Posted Date
2016-04-13
Last Posted Date
2024-07-12
Lead Sponsor
UMC Utrecht
Target Recruit Count
20000
Registration Number
NCT02735707
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

🇺🇸

University of Illinois Health, Chicago, Illinois, United States

🇦🇺

Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations
© Copyright 2024. All Rights Reserved by MedPath